Kelly M. Rausch - Concepedia

Author

Kelly M. Rausch

National Institute of Allergy and Infectious Diseases ORCID

Also Known As

Kelly M. Rausch, Kelly M Rausch, Kelly M. Rausch, Kelly Rausch

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

National Institute of Allergy and Infectious Diseases National Institutes of Health Vector Oncology (United States)Johns Hopkins University Karolinska Institutet

About

Kelly M. Rausch is an author at National Institute of Allergy and Infectious Diseases specializing in medicine, vaccination, and malaria.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	15	835
2	Biochemistry	3	3	325
3	Engineering	2	2	122
4	Natural Sciences	2	2	294
5	Public Health	1	1	24

Kelly M. Rausch

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51 Yimin Wu, Ruth D. Ellis, Donna Shaffer, PLoS ONE	2008	450
Composite Active Site of an ABC ATPase M.S. Junop, Galina Obmolova, Kelly M. Rausch, Molecular Cell Cellular EnzymologyBiochemistryNatural SciencesEnzyme CatalysisMolecular Biology	2001	264
Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults Kawsar R. Talaat, Ruth D. Ellis, Janet Hurd, PLoS ONE Vaccine ResearchMalariaImmunologyPlasmodium FalciparumParasite Genomics	2016	135
Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230 Nicholas J. MacDonald, Vu Nguyen, Richard L. Shimp, Journal of Biological Chemistry	2016	107
Pfs230 yields higher malaria transmission–blocking vaccine activity than Pfs25 in humans but not mice Sara A. Healy, Charles Anderson, Bruce Swihart, Journal of Clinical Investigation	2021	106
Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle Richard L. Shimp, Christopher G. Rowe, Karine Reiter, Vaccine VaccinationNanomedicineNanoparticlesEngineeringNanomaterials	2013	101
Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults Issaka Sagara, Sara A. Healy, Mahamadoun H. Assadou, The Lancet Infectious Diseases VaccinationVaccine SafetyTransmission-blocking VaccineMalariaImmunology	2018	101
Montanide® ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations Aaron P. Miles, Holly McClellan, Kelly M. Rausch, Vaccine VaccinationVaccine DevelopmentVaccine FormulationsMedicineImmunology	2004	99
Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909 C.J. Duncan, Susanne H. Sheehy, Katie Ewer, PLoS ONE	2011	94
A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel®+ CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults Issaka Sagara, Ruth D. Ellis, Alassane Dicko, Vaccine	2009	82

Page 1